2020-03-23

Press releases regulatory

2cureX provides update regarding the COVID-19 impact on ongoing clinical programs

Copenhagen — March 23, 2020 — 2cureX AB (“2cureX”, NASDAQ: 2CUREX) announced today that the corona-crisis will not delay 2cureX’s...

2020-03-06

Press releases regulatory

2cureX is accelerating the commercialization of IndiTreat® by signing two distributor agreements to prepare for launch in second half of 2020

2cureX AB (“2cureX”, NASDAQ: 2CUREX) today announces that the company has established two partnership agreements to support the commercialization of...

2020-02-28

Press releases regulatory

2cureX publishes year-end report for 2019

2cureX AB (“2cureX”) hereby publishes the year-end report for the fourth quarter and the fiscal year 2019. The year-end report...

2020-01-30

Press releases

Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce that 35 patients have been treated in accordance with the IndiTreat...

2020-01-06

Press releases regulatory

2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce the granting of an Australian patent (AU2015283320A) on its key product,...

2019-12-13

Press releases regulatory

2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019.

2cureX AB (“2cureX”, NASDAQ: 2CUREX) announces that the company presented significant progression of the IndiTreat® test for individualizing immuno-oncological treatment...